CONCORD HC GP announced that on May 10, 2026, the company entered into a placing and subscription agreement with a placing agent and a subscriber. Under this agreement, the company will issue, and the subscriber will subscribe for, bonds with a total principal amount of HK$68 million. These are 2% convertible bonds due in 2027, subject to the terms of the agreement. The initial conversion price is set at HK$1.7 per share, representing a premium of approximately 14.09% over the closing price of HK$1.49 per share on May 8, 2026, the last trading day before the agreement was signed. Based on this initial conversion price and assuming full conversion, the bonds could be converted into 40 million H shares. This would represent about 12.74% of the company's existing issued H shares and approximately 5.10% of its total issued share capital as of the announcement date. The subscriber, Jiaxi Holdings Limited, is a wholly-owned subsidiary of CSPC Pharmaceutical Group. Leveraging CSPC's deep pharmaceutical industry background and leading market position, CONCORD HC GP will deepen its strategic cooperation with CSPC to create positive business synergies, which is expected to support the group's long-term operational improvement in the oncology medical field. The gross proceeds from the bond issuance amount to HK$68 million, with net proceeds estimated to be approximately HK$63.1 million. The company intends to use the net proceeds as follows: (a) approximately 70% will be used to repay loans provided by financial institutions to the company and its subsidiaries, including principal and interest for working capital loans, fixed asset loans, and finance lease liabilities, expected to be fully utilized by December 31, 2026; and (b) approximately 30% will be used to supplement the working capital of the company and its subsidiaries for general corporate purposes, also expected to be fully utilized by December 31, 2026.